Related Experiment Videos
Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study
W G Ondo1, K D Vuong, H S Derman
1Department of Neurology, Baylor College of Medicine, 6556 Fannin, Suite 1801, Houston, TX 77030, USA. wondo@bcm.tmc.edu
Cephalalgia : an International Journal of Headache
|December 23, 2003
Summary
Botulinum toxin type A (BTX) shows promise for chronic daily headaches, improving headache-free days and patient-reported outcomes. This treatment was well-tolerated and may have cumulative effects with repeated injections.
Area of Science:
- Neurology
- Pharmacology
Background:
- Chronic daily headache, including chronic tension-type and chronic migraine, significantly impacts quality of life.
- Botulinum toxin type A (BTX) is an established treatment for certain neurological conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of BTX for chronic daily headaches.
- To assess the impact of BTX on headache frequency, medication use, and patient/investigator global impressions.
Main Methods:
- A 12-week, double-blind, placebo-controlled study involving 60 patients with chronic daily headaches.
- Patients received either 200 U of BTX or placebo, with headache frequency tracked via diaries.
- Secondary endpoints included global impressions and use of abortive medications.
Main Results:
- The BTX group showed a statistically significant improvement in headache-free days from week 8 to 12 (P < 0.05).
- Patient and investigator global impressions significantly improved in the BTX group compared to placebo (P < 0.05 and P < 0.001, respectively).
- Adverse events were mild and comparable between groups. A cumulative effect was observed with repeated BTX injections.
Conclusions:
- Botulinum toxin type A (BTX) appears to be an effective and well-tolerated treatment for chronic daily headaches.
- BTX may offer a cumulative benefit with repeated administrations, warranting further investigation for chronic headache management.